Dataset Information

Nucleus segmentation across imaging experiments: the 2018 Data Science Bowl.

ABSTRACT: Segmenting the nuclei of cells in microscopy images is often the first step in the quantitative analysis of imaging data for biological and biomedical applications. Many bioimage analysis tools can segment nuclei in images but need to be selected and configured for every experiment. The 2018 Data Science Bowl attracted 3,891 teams worldwide to make the first attempt to build a segmentation method that could be applied to any two-dimensional light microscopy image of stained nuclei across experiments, with no human interaction. Top participants in the challenge succeeded in this task, developing deep-learning-based models that identified cell nuclei across many image types and experimental conditions without the need to manually adjust segmentation parameters. This represents an important step toward configuration-free bioimage analysis software tools.

SUBMITTER: Caicedo JC

PROVIDER: S-EPMC6919559 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Nucleus segmentation across imaging experiments: the 2018 Data Science Bowl.

Caicedo Juan C JC Goodman Allen A Karhohs Kyle W KW Cimini Beth A BA Ackerman Jeanelle J Haghighi Marzieh M Heng CherKeng C Becker Tim T Doan Minh M McQuin Claire C Rohban Mohammad M Singh Shantanu S Carpenter Anne E AE

Nature methods 20191021 12

Segmenting the nuclei of cells in microscopy images is often the first step in the quantitative analysis of imaging data for biological and biomedical applications. Many bioimage analysis tools can segment nuclei in images but need to be selected and configured for every experiment. The 2018 Data Science Bowl attracted 3,891 teams worldwide to make the first attempt to build a segmentation method that could be applied to any two-dimensional light microscopy image of stained nuclei across experim ...[more]

PMID: 31636459

Similar Datasets

Project description:Progress in neuro-oncology is increasingly recognized to be obstructed by the marked heterogeneity-genetic, pathological, and clinical-of brain tumours. If the treatment susceptibilities and outcomes of individual patients differ widely, determined by the interactions of many multimodal characteristics, then large-scale, fully-inclusive, richly phenotyped data-including imaging-will be needed to predict them at the individual level. Such data can realistically be acquired only in the routine clinical stream, where its quality is inevitably degraded by the constraints of real-world clinical care. Although contemporary machine learning could theoretically provide a solution to this task, especially in the domain of imaging, its ability to cope with realistic, incomplete, low-quality data is yet to be determined. In the largest and most comprehensive study of its kind, applying state-of-the-art brain tumour segmentation models to large scale, multi-site MRI data of 1251 individuals, here we quantify the comparative fidelity of automated segmentation models drawn from MR data replicating the various levels of completeness observed in real life. We demonstrate that models trained on incomplete data can segment lesions very well, often equivalently to those trained on the full completement of images, exhibiting Dice coefficients of 0.907 (single sequence) to 0.945 (complete set) for whole tumours and 0.701 (single sequence) to 0.891 (complete set) for component tissue types. This finding opens the door both to the application of segmentation models to large-scale historical data, for the purpose of building treatment and outcome predictive models, and their application to real-world clinical care. We further ascertain that segmentation models can accurately detect enhancing tumour in the absence of contrast-enhancing imaging, quantifying the burden of enhancing tumour with an R 2 > 0.97, varying negligibly with lesion morphology. Such models can quantify enhancing tumour without the administration of intravenous contrast, inviting a revision of the notion of tumour enhancement if the same information can be extracted without contrast-enhanced imaging. Our analysis includes validation on a heterogeneous, real-world 50 patient sample of brain tumour imaging acquired over the last 15 years at our tertiary centre, demonstrating maintained accuracy even on non-isotropic MRI acquisitions, or even on complex post-operative imaging with tumour recurrence. This work substantially extends the translational opportunity for quantitative analysis to clinical situations where the full complement of sequences is not available and potentially enables the characterization of contrast-enhanced regions where contrast administration is infeasible or undesirable.

Dataset Information

Nucleus segmentation across imaging experiments: the 2018 Data Science Bowl.

Publications

Nucleus segmentation across imaging experiments: the 2018 Data Science Bowl.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets